Clinical Trial Update: Study of Neoadjuvant Olaparib Monotherapy and Olaparib and Durvalumab Combination in HER2 Negative BRCAm Breast Cancer [Phase 2]

View source ↗

Summary

A Phase 2 neoadjuvant study is evaluating olaparib alone and in combination with durvalumab in HER2-negative, BRCA-mutated breast cancer; the trial is currently…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• IMFINZI (DURVALUMAB)
• Lynparza (olaparib)

Snippet

Sponsor: AstraZeneca | Conditions: Breast Cancer | Phase 2 | Status: ACTIVE_NOT_RECRUITING